In this online CME self-learning program:
Parkinson's, a central nervous system disease of the autonomic and basal ganglia, neocortex, and spinal cord, is thought to affect about one million people in the United States. Its etiology has yet to be fully elucidated, although they are thought to include a confluence of factors including age, genetic predisposition, comorbid disease states (e.g., Gaucher’s disease), and environmental factor dynamics. Present in 1% of people over age 65 and 2.5% of those older than 80, its symptoms are the direct result of dopaminergic neuronal degradation along the nigrostriatal tract and include bradykinesia, resting tremor, muscle rigidity, and gait disturbance.
Goals of the care are to restore lost motor and non-motor function and improve patient quality-of-life. Treatment section is contingent primarily upon to what degree the disease has already advanced and comorbidities and is characterized by frequent dose titrations and additions of therapies with different mechanisms of action.
-Faculty member introduction, disclosures
-Major findings from AAN 2017, including clinical trial data relevant to both community and health-system practice and recognized barriers to implementing those findings in practice (specific content contingent upon conference content)
Neurologists and any other healthcare professionals who otherwise come into regular clinical contact with and provide care for patients with Parkinson’s disease.
This program is supported by an educational grant from Valeant.
Release Date: June 16, 2017 -- Expiration Date: June 16, 2019
Faculty: Laxman Bahroo, MD
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Laxman Bahroo, M.D. is a consultant and/or on the speaker's bureau for: Allergan, Teva, Ipsen, Merz, Xenoport, Impax, Abbvie, UCB, Lundbeck, Acadia, Neurocrine
Disclosures of Educational Planners: Charles Turck, PharmD has no relevant conflicts of interest to disclose.
Commercial Support Disclosure: This program is supported by an educational grant from Valeant.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.